Johnson & Johnson: real-world data show lower mortality with Impella in HRPCI
Johnson & Johnson reported three real-world analyses of HRPCI patients supported by Impella versus CHIP-BCIS3. Source: TradingView, citing a BusinessWire release.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Johnson & Johnson presented three analyses based on real-world data from the U.S. and EU. Patients with HRPCI who were supported by Impella showed lower in-hospital mortality, as well as lower mortality at 30 and 90 days, compared with CHIP-BCIS3. The analysis included 1,379 patients.
Results from the PROTECT IV randomized trial are expected in 2027. The new data add to earlier observational and registry findings on Impella in HRPCI.
why it matters
For investors, the news matters more as confirmation of long-term interest in the product than as a sharp shift in revenue. Data from a large sample of real patients can influence physician practice and reimbursement decisions. A bigger catalyst would be the PROTECT IV trial, along with any changes to clinical guidelines or payment rules.
market impact
JNJ: positive Impella data could support physician interest and demand for the device.
tags
instruments
sources
- Johnson & Johnson (JNJ) Reports Positive Real-World Impella HRPCI Outcomes vs CHIP-BCIS3 — TradingView, 1 November 2026 at 13:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗